Ardelyx, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Dec 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Feb 8 to 27, 2027 · next Feb 8
- 2 fees due Mar 12 to 26, 2027 · next Mar 12
- 1 fee due May 14, 2027The maintenance fee for Compounds and Methods for Inhibiting Phosphate Transport (US 11,813,304) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Jul 2 to 28, 2027 · next Jul 2
- 3 fees due Sep 8 to 22, 2027 · next Sep 8
- 1 fee due Oct 5, 2027The maintenance fee for Compounds and Methods for Inhibiting Phosphate Transport (US 9,301,951) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,969,377 | Compounds and Methods for Inhibiting Nhe-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders In force · Low confidence | In force | Low confidence | |
| US 9,408,840 | Compounds and Methods for Inhibiting Nhe-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorder In force · Low confidence | In force | Low confidence | |
| US 10,543,207 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 11,318,129 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 12,016,856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,006,281 | Compounds and Methods for Inhibiting Nhe-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders In force · Medium confidence | In force | Medium confidence | |
| US 8,809,339 | Compounds and Methods for Inhibiting Phosphate Transport In force · Medium confidence | In force | Medium confidence | |
| US 8,815,908 | Compounds and Methods for Inhibiting Phosphate Transport In force · Medium confidence | In force | Medium confidence | |
| US 8,815,910 | Compounds and Methods for Inhibiting Phosphate Transport In force · Medium confidence | In force | Medium confidence | |
| US 8,916,569 | Compounds and Methods for Inhibiting Phosphate Transport In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 6 abandoned · 8 no status recorded